一項最新研究提示抗血小板藥物例如阿司匹林，不會增加顱內(nèi)出血(ICH)后進一步出血的危險。

這項研究涉及了127例患者小葉顱內(nèi)出血患者和80例重度顱內(nèi)出血的患者，這些患者1994年至2004年在麻省總院(Boston, MA, USA)接受了治療，在顱內(nèi)出血后6個月接受隨訪，以后每個6個月同樣接受隨訪。這些研究結(jié)果在2006年1月24日的《神經(jīng)病學(xué)》期刊上進行了報道。

在隨訪期間，56例患者開始使用阿司匹林，1例clopidogrel。適應(yīng)癥包括缺血性心臟疾病、房顫、人造瓣膜、缺血性腦卒中、暫時系性缺血性發(fā)作。39例患者出現(xiàn)再發(fā)性顱內(nèi)缺血。分析顯示：小葉顱內(nèi)出血或者重度顱內(nèi)出血幸存者中使用抗血小板藥物，與再發(fā)出血危險增高之間并不相關(guān)。

Aspirin Use Safe After Intracerebral Hemorrhage
 
A new study suggests that antiplatelet agents such as aspirin do not increase the risk of a further recurrence following an intracerebral hemorrhage (ICH).

The study included 127 patients with lobar ICH and 80 with deep ICH who had been treated at Massachusetts General Hospital (Boston, MA, USA) between 1994 and 2004 and were interviewed at three and six months post ICH and every six months thereafter. The results were reported in the January 24, 2006, issue of Neurology.

Forty-six of the subjects began using aspirin, or in one case clopidogrel, during follow-up. Indications included ischemic heart disease, atrial fibrillation, artificial heart valve, ischemic stroke, and transient ischemic attack. There were 39 subjects with recurrent ICH. Analyses showed that antiplatelet agents were not associated with a significantly increased risk of recurrent hemorrhage among lobar ICH survivors or deep ICH survivors.